HealiusASX:HLS -5.13%54 3-Year ROIIC % is 14.33 as of Jun. 2025, which is 32% above its 10-year median of 10.89. GuruFocus rates ASX:HLS with a GF Score™ of 54/100 and a GF Value™ of A$1.01 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Healius ranks better than 63.55% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Healius's 3-Year ROIIC % for the quarter that ended in Jun. 2025 was 14.33%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Healius's 3-Year ROIIC % or its related term are showing as below:
ASX:HLS's 3-Year ROIIC % is ranked better than 63.55% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.22
vs ASX:HLS: 14.33
Healius (ASX:HLS) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Healius 3-Year ROIIC % Related Terms
Healius 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Healius's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:HLS vs TMO, DHR, IDXX: 3-Year ROIIC % Comparison
For the Diagnostics & Research subindustry, Healius's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Healius 3-Year ROIIC % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Healius's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Healius's 3-Year ROIIC % falls into.
Healius's 3-Year ROIIC % for the quarter that ended in Jun. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 0.19018 (Jun. 2025) - 344.06708 (Jun. 2022) )
/
( 1837.4 (Jun. 2025) - 4236.7 (Jun. 2022) )
=
-343.8769
/
-2399.3
=
14.33%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Healius (ASX:HLS) has a 3-Year ROIIC % of 14.33 as of Jun. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Healius and its competitors. This is 32% above median its historical median of 10.89. According to the industry distribution chart, Healius ranks #74 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 36.5%.
Is Healius' 3-Year ROIIC % too high?
Healius' current 3-Year ROIIC % of 14.33 is 32% above median its 10-year median of 10.89. The Medical Diagnostics & Research industry median 3-Year ROIIC % is 0.22. Healius' value of 14.33 is 6413.6% above this industry median. Based on the distribution chart, Healius ranks #74 out of 203 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Healius has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Healius' 3-Year ROIIC % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Healius ranks #74 out of 203 companies for 3-Year ROIIC %. This puts Healius in the upper half of its industry. The industry median 3-Year ROIIC % is 0.22. Healius' value of 14.33 is 6413.6% above this benchmark. While the company's 10-year median is 10.89 vs. the industry median of 0.22, Healius has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Diagnostics & Research company?
The median 3-Year ROIIC % among Medical Diagnostics & Research companies is 0.22, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Healius's current 3-Year ROIIC % of 14.33 is 6413.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Healius and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year ROIIC % is 0.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Healius's current 3-Year ROIIC % is 14.33, which is 32% above median its own 10-year median of 10.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healius stock overvalued right now?
Based on GuruFocus' analysis, Healius (ASX:HLS) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.01, compared to a current price of A$0.37 — trading 63.4% below its estimated fair value. The current 3-Year ROIIC % is 14.33, which is 32% above median its 10-year median of 10.89 and 6413.6% above the Medical Diagnostics & Research industry median of 0.22. Healius' overall GF Score™ is 54/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Healius (ASX:HLS), the current 3-Year ROIIC % is 14.33 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Healius (ASX:HLS) Overvalued in 2026?
Based on GuruFocus' analysis, Healius stock appears to be undervalued.
The current stock price of A$0.37 is trading 63.4% below its estimated GF Value™ of A$1.01.
GuruFocus considers Healius to be Possible Value Trap.
Key valuation signals for ASX:HLS:
3-Year ROIIC %: 14.33 (32% above median its 10-year median of 10.89)
GF Value™: A$1.01 vs. price of A$0.37 (63.4% below fair value)
Industry Position: 6413.6% above the Medical Diagnostics & Research median (#74 of 203)
No single metric tells the full story. See the ASX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Healius is Australia's second-largest pathology provider. Pathology revenue is almost entirely earned via the public health Medicare system and makes up the majority of Healius' group revenue. A small portion comes from its clinical testing business, Agilex.
54GF Score
Get the complete analysis for ASX:HLS
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:HLS has been successfully added to your 
